saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
Open Access
- 19 May 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Abstract
Several vaccines have been widely used to counteract the global pandemic caused by SARS-CoV-2. However, due to the rapid emergence of SARS-CoV-2 variants of concern (VOCs), further development of vaccines that confer broad and longer-lasting protection against emerging VOCs are needed. Here, we report the immunological characteristics of a self-amplifying RNA (saRNA) vaccine expressing the SARS-CoV-2 Spike (S) receptor binding domain (RBD), which is membrane-anchored by fusing with an N-terminal signal sequence and a C-terminal transmembrane domain (RBD-TM). Immunization with saRNA RBD-TM delivered in lipid nanoparticles (LNP) efficiently induces T-cell and B-cell responses in non-human primates (NHPs). In addition, immunized hamsters and NHPs are protected against SARS-CoV-2 challenge. Importantly, RBD-specific antibodies against VOCs are maintained for at least 12 months in NHPs. These findings suggest that this saRNA platform expressing RBD-TM will be a useful vaccine candidate inducing durable immunity against emerging SARS-CoV-2 strains.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627, JP21nf0101627)
This publication has 32 references indexed in Scilit:
- Influenza hemagglutinin membrane anchorProceedings of the National Academy of Sciences, 2018
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responsesJournal of Experimental Medicine, 2018
- Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower DosesMolecular Therapy, 2018
- Recombinant influenza H9N2 virus with a substitution of H3 hemagglutinin transmembrane domain showed enhanced immunogenicity in mice and chickenScientific Reports, 2017
- Developing mRNA-vaccine technologiesRNA Biology, 2012
- Enzymatic assembly of DNA molecules up to several hundred kilobasesNature Methods, 2009
- An Alphavirus Replicon Particle Chimera Derived from Venezuelan Equine Encephalitis and Sindbis Viruses Is a Potent Gene-Based Vaccine Delivery VectorJournal of Virology, 2003
- Replicon-Helper Systems from Attenuated Venezuelan Equine Encephalitis Virus: Expression of Heterologous Genesin Vitroand Immunization against Heterologous Pathogensin VivoVirology, 1997
- Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures.The Journal of Immunology, 1988
- A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12American Journal of Epidemiology, 1938